This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
TruBridge Dividendes et rachats
Dividende contrôle des critères 0/6
TruBridge ne verse actuellement pas de dividende.
Informations clés
0%
Rendement du dividende
0.4%
Rendement des rachats
| Rendement total pour l'actionnaire | 0.4% |
| Rendement futur des dividendes | 0% |
| Croissance des dividendes | n/a |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Ratio de distribution | 0% |
Mises à jour récentes sur les dividendes et les rachats
Pas de mise à jour
Recent updates
Mise à jour du récit • Jul 10
TBRG: IKS Deal, Legal Probes And Reclassified Outlook Will Shape Re Rating
Analysts have lifted the TruBridge price target from $22.00 to about $25.44, citing updated assumptions around revenue growth, profit margins and a lower P/E multiple. This view is supported by recent research that includes both price target increases and rating downgrades, as well as commentary on the potential IKS acquisition.
Mise à jour du récit • Jun 26
TBRG: Pending IKS Buyout Will Likely Expose Execution Risks
The analyst price target for TruBridge has moved from $15 to $23. Analysts attribute this change to adjustments in fair value assumptions, a lower discount rate, and updated expectations for revenue growth, profit margins, and future P/E.Mise à jour du récit • Apr 17
TBRG: Potential IKS Deal And EHR Execution Will Shape Future Re Rating
TruBridge's analyst fair value estimate has shifted from $21.00 to $22.00 as analysts update their models around potential IKS-related opportunities, as well as recent mixed price target moves across the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to the potential IKS transaction as aligned with TruBridge's ongoing review of its business.
Nouveau récit • Apr 16
AI And Global Delivery Expansion Will Reshape Rural Hospital Solutions Over The Next Decade
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and patient care software and services to hospitals, with a focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 14
TruBridge: Potential Takeover Target, Upside Fundamentally Supported
Summary TruBridge, Inc. is undergoing an operational turnaround with margin expansion, rising EBITDA, and a shift to high-quality recurring revenue. A potential $600 million takeover by Inventurus Knowledge Systems offers a 36–40% premium to current prices but introduces binary deal risk. TBRG’s recurring revenue remains high at 94%, with stable cash flows and improved profitability despite flat top-line growth. The implied takeover valuation aligns with sector multiples, suggesting the upside is fundamentally supported, not purely speculative. Read the full article on Seeking AlphaMise à jour du récit • Apr 02
TBRG: Revenue Cycle Momentum And EHR Stability Will Support Future Re Rating
Analysts have trimmed their price targets on TruBridge, with the average moving from about $22.67 to $21.00 as they weigh a slightly higher discount rate, modestly different revenue growth and margin assumptions, and a lower future P/E multiple against the company's mix of Revenue Cycle Management growth potential and stable Electronic Health Records operations. Analyst Commentary Recent research updates on TruBridge reflect a mix of optimism around the business model and caution around execution and valuation.Nouveau récit • Apr 02
AI Expansion And Global Delivery Shift Will Shape A Steady But Capped Future
Catalysts About TruBridge TruBridge provides revenue cycle, financial health and electronic health record solutions to hospitals and healthcare providers, with a particular focus on rural and community facilities. What are the underlying business or industry changes driving this perspective?Article d’analyse • Feb 12
Returns At TruBridge (NASDAQ:TBRG) Appear To Be Weighed Down
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Mise à jour du récit • Jan 28
TBRG: Revenue Cycle Focus And EHR Stability Will Test Execution Outcomes
Narrative Update The analyst price target for TruBridge has shifted modestly higher to about $22.67 per share, supported by analysts citing the potential of its Revenue Cycle Management focus alongside a steadier Electronic Health Records business, while still calling out execution risk after recent periods of low growth. Analyst Commentary Recent research points to a mixed but constructive view on TruBridge, with analysts focusing on the shift toward Revenue Cycle Management and the steadier Electronic Health Records business when considering valuation and execution risk.Mise à jour du récit • Jan 12
TBRG: Revenue Cycle Realignment And EHR Stability Will Require Steady Execution
Narrative Update The analyst price target for TruBridge now centers around US$23, a modest lift from the prior US$22.60. Analysts point to the potential of the Revenue Cycle Management opportunity alongside a steadier Electronic Health Records business, while still flagging execution risk after recent periods of low growth.Mise à jour du récit • Dec 17
TBRG: Revenue Cycle Shift Will Demand Proven Execution Before Rerating
Analysts raised their price target on TruBridge modestly, citing improving growth prospects from the company’s shift toward revenue cycle management as evidence builds of its long-term earnings potential. Analyst Commentary Bullish Takeaways Bullish analysts view the company’s realignment toward revenue cycle management as a structurally higher growth opportunity compared with its legacy clinical software offerings.Mise à jour du récit • Dec 03
TBRG: Revenue Cycle Pivot Will Require Clear Execution Evidence In 2025
Analysts have nudged their price target on TruBridge slightly higher to approximately $22.60 per share. This reflects increased confidence that the company’s shift toward revenue cycle management can unlock more attractive, evidence-based growth than its legacy clinical software focus.Mise à jour du récit • Nov 19
TBRG: Measured Optimism Will Depend On Evidence Of Execution In 2025
TruBridge's analyst price target has been revised downward from $24.75 to $22.60. Analysts cite recent coverage reflecting cautious optimism about the company's strategic shift toward revenue cycle management, while awaiting clearer evidence of execution before turning more positive.Article d’analyse • Nov 14
Solid Earnings Reflect TruBridge's (NASDAQ:TBRG) Strength As A Business
Even though TruBridge, Inc.'s ( NASDAQ:TBRG ) recent earnings release was robust, the market didn't seem to notice. We...Mise à jour du récit • Aug 15
AI And India Hub Will Boost Future Healthcare Efficiency
Despite a notable improvement in TruBridge’s net profit margin and a significant decline in its future P/E ratio, the consensus analyst price target has been sharply revised down from $29.25 to $24.75. What's in the News TruBridge lowered its full-year 2025 revenue guidance to $345 million-$350 million from a previous range of $345 million-$360 million; third quarter 2025 revenue is forecasted at $85 million-$87 million.Nouveau récit • May 31
Digital Automation And AI Will Drive Healthcare Transformation
Increased AI-driven automation, expanded SaaS offerings, and digital transformation are expected to boost operational efficiency, recurring revenue growth, and earnings quality.Article d’analyse • Feb 14
Would TruBridge (NASDAQ:TBRG) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jan 17
TruBridge, Inc. (NASDAQ:TBRG) Shares Fly 27% But Investors Aren't Buying For Growth
TruBridge, Inc. ( NASDAQ:TBRG ) shares have continued their recent momentum with a 27% gain in the last month alone...Article d’analyse • Nov 13
TruBridge, Inc.'s (NASDAQ:TBRG) Business And Shares Still Trailing The Industry
TruBridge, Inc.'s ( NASDAQ:TBRG ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de TBRG ont été stables dans le passé.
Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de TBRG ont augmenté.
Rendement des dividendes par rapport au marché
| TruBridge Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (TBRG) | 0% |
| 25% du marché (US) | 1.3% |
| 25% du marché (US) | 4.0% |
| Moyenne du secteur (Healthcare Services) | 1.1% |
| Analyste prévisionnel (TBRG) (jusqu'à 3 ans) | 0% |
Dividende notable: Impossible d'évaluer le rendement des dividendes de TBRG par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.
Dividende élevé: Impossible d'évaluer le rendement des dividendes de TBRG par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.
Bénéfice distribué aux actionnaires
Couverture des revenus: TBRG ne verse pas de dividende notable pour le marché US.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car TBRG n'a signalé aucun versement.
Découvrir des entreprises qui versent des dividendes élevés
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 13:02 |
| Cours de l'action en fin de journée | 2026/07/08 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
TruBridge, Inc. est couverte par 22 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Stephanie Davis | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |